Barriers to HCV treatment in the era of triple therapy: a prospective multi-centred study in clinical practice

摘要: Background & Aims (i) To describe the demographic, clinical, virological and histological characteristics of patients undergoing evaluation for indication triple therapy against hepatitis C virus genotype 1, to identify reasons why candidate are excluded; (ii) evaluate healthcare environment related treatment. Methods Observational, prospective multi-centred study involving 16 hospitals Spain. Data were collected on 1122 receiving attention in outpatient clinics between June December 2012. Results Of evaluated, 769 finally included this study; 27% (211/769) had contraindications therapy. Of those without contraindications, 54% (301/558) did not receive treatment, so, only about a third (33%–257/769) underwent The initiating as follows: patient refusal (30%), mild disease/awaiting new treatments (34%), restrictions by health service other (6%). In univariate analyses, probability treatment was to: age <60 years, male gender, high education level, advanced fibrosis, having previous being assessed centre excellence. multivariate factors independently level (P = 0.004), fibrosis (P < 0.001) centres excellence (P = 0.009). Conclusion Despite efficacy therapy, small proportion treatment. causes non-treatment depend factors, disease stage health-service provision.